Related Experiment Video

Updated: Aug 16, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

Virus-like Particles for TEM Regulation and Antitumor Therapy

Zhu Yang1,2, Yongjie Chi1,2, Jiaxin Bao1,3

  • 1Key Laboratory of Green Process and Engineering, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.

Journal of Functional Biomaterials
|December 22, 2022
PubMed

Insights

Virus-like particles (VLPs) offer a novel nanocarrier solution for cancer immunotherapy, overcoming drug delivery challenges within the tumor microenvironment (TME). Their design allows for TME targeting to enhance long-term cancer treatment efficacy.

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Immunology

Background:

  • Tumor development and metastasis are linked to the tumor microenvironment (TME).
  • Conventional vector-restricted drugs face challenges in achieving long-term efficacy within the TME for cancer immunotherapy.
  • Virus-like particles (VLPs) are emerging as promising nanocarriers for therapeutic applications.

Purpose of the Study:

  • To review the design principles of virus-like particles (VLPs) as nanocarriers.
  • To explore the advancements in utilizing VLPs for regulating the tumor microenvironment (TME) in cancer immunotherapy.

Main Methods:

  • Review of scientific literature on VLP design and TME targeting strategies.
  • Analysis of VLP properties, including size, self-assembly, and immunogenicity.
  • Examination of VLP surface modification techniques for enhanced TME interaction.

Main Results:

  • VLPs, self-assembled from viral proteins, range from 20-200 nm and can induce humoral immunity.
  • VLP surfaces can be genetically or chemically modified for targeted delivery to the TME.
  • VLPs demonstrate potential for overcoming drug delivery limitations in cancer immunotherapy.

Conclusions:

  • Virus-like particles (VLPs) present a versatile platform for nanocarrier development in cancer immunotherapy.
  • Targeted VLP delivery to the TME is a key strategy for enhancing therapeutic outcomes.
  • Further research into VLP design and functionalization is crucial for advancing cancer treatment.
Keywords:
immunotherapynanovaccinetumor microenvironmentvirus-like particle

More Related Videos

Viral Nanoparticles for In vivo Tumor Imaging14:04

Viral Nanoparticles for In vivo Tumor Imaging

Published on: November 16, 2012

17.3K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
624
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
74